Novel Genetic Melanoma Vaccines Based on Induced Pluripotent Stem Cells or Melanosphere-Derived Stem-Like Cells Display High Efficacy in a murine Tumor Rejection Model
暂无分享,去创建一个
A. Mackiewicz | Jakub Jankowski | A. Kozłowska | Eliza Kwiatkowska-Borowczyk | Agnieszka Gąbka-Buszek
[1] Sakshi Sahni,et al. Role of Anti-PD-1 Antibodies in Advanced Melanoma: The Era of Immunotherapy , 2018, Cureus.
[2] A. Mackiewicz,et al. Re-induction using whole cell melanoma vaccine genetically modified to melanoma stem cells-like beyond recurrence extends long term survival of high risk resected patients - updated results , 2018, Journal of Immunotherapy for Cancer.
[3] P. Dong,et al. Tumor-Intrinsic PD-L1 Signaling in Cancer Initiation, Development and Treatment: Beyond Immune Evasion , 2018, Front. Oncol..
[4] Patrycja Czerwińska,et al. Whole cell melanoma vaccine genetically modified to stem cells like phenotype generates specific immune responses to ALDH1A1 and long-term survival in advanced melanoma patients , 2018, Oncoimmunology.
[5] Mark M. Davis,et al. Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. , 2018, Cell stem cell.
[6] K. Kabashima,et al. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..
[7] K. Khanna,et al. Combination Immunotherapy: Taking Cancer Vaccines to the Next Level , 2018, Front. Immunol..
[8] J. Dou,et al. Effective tumor immunity to melanoma mediated by B16F10 cancer stem cell vaccine , 2017, International Immunopharmacology.
[9] A. Mackiewicz,et al. Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma , 2017, Contemporary oncology.
[10] K. Kaur,et al. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs , 2017, Journal of Cancer.
[11] K. Kaur,et al. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice. , 2017, Frontiers in bioscience.
[12] C. Aspord,et al. Melanoma dormancy in a mouse model is linked to GILZ/FOXO3A-dependent quiescence of disseminated stem-like cells , 2016, Scientific Reports.
[13] Marzieh Ebrahimi,et al. Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses. , 2016, Cancer letters.
[14] K. Kaur,et al. Adoptive transfer of osteoclast-expanded natural killer cells for immunotherapy targeting cancer stem-like cells in humanized mice , 2016, Cancer Immunology, Immunotherapy.
[15] Kaori Tanaka,et al. Aldehyde dehydrogenase 1A1 in stem cells and cancer , 2016, Oncotarget.
[16] Yujiang Fang,et al. The paradoxical role of IL-10 in immunity and cancer. , 2015, Cancer letters.
[17] M. Serrano,et al. The pluripotency factor NANOG promotes the formation of squamous cell carcinomas , 2015, Scientific Reports.
[18] R. Stefan,et al. Whole Cell Therapeutic Vaccine Modified With Hyper-IL6 for Combinational Treatment of Nonresected Advanced Melanoma , 2015, Medicine.
[19] A. Mackiewicz,et al. Immunotargeting of cancer stem cells , 2015, Contemporary oncology.
[20] C. Creighton,et al. VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2 , 2014, Oncogene.
[21] N. Popitsch,et al. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients , 2013, Clinical Cancer Research.
[22] A. Mackiewicz,et al. Therapeutic gene modified cell based cancer vaccines. , 2013, Gene.
[23] Baocun Sun,et al. The in-vitro spheroid culture induces a more highly differentiated but tumorigenic population from melanoma cell lines , 2013, Melanoma research.
[24] I. Mellman,et al. Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.
[25] Masashi Kato,et al. Inflammatory monocytes are potent antitumor effectors controlled by regulatory CD4+ T cells , 2013, Proceedings of the National Academy of Sciences.
[26] M. Wiznerowicz,et al. Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection , 2012, Expert opinion on investigational drugs.
[27] A. Mackiewicz,et al. Design of clinical trials for therapeutic cancer vaccines development. , 2009, European journal of pharmacology.
[28] Eric Vivier,et al. Functions of natural killer cells , 2008, Nature Immunology.
[29] J. Scheller,et al. The IL-6/sIL-6R complex as a novel target for therapeutic approaches , 2007, Expert opinion on therapeutic targets.
[30] Ugo Orfanelli,et al. Isolation and Characterization of Tumorigenic, Stem-like Neural Precursors from Human Glioblastoma , 2004, Cancer Research.
[31] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[32] H. Ertl,et al. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16. , 2001, Vaccine.
[33] P. Schirmacher,et al. The designer cytokine hyper-IL-6 mediates growth inhibition and GM–CSF-dependent rejection of B16 melanoma cells , 2001, Oncogene.
[34] S. Rose-John,et al. A bioactive designer cytokine for human hematopoietic progenitor cell expansion , 1997, Nature Biotechnology.